advertisement
Abstract #17531 Published in IGR 9-2
Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients
Martinez A; Sanchez MInternational Journal of Clinical Pract 2007; 61: 815-825
The objective of this study was to compare the effect of the latanoprost/timolol fixed combination (LTFC) and the dorzolamide/timolol fixed combination (DTFC) on the retrobulbar haemodynamic and intraocular pressure (IOP) in patents with open-angle glaucoma (OAG). This was a prospective, examiner masked, randomised and crossover study. Participants were 32 consecutive subjects, who met the inclusion/exclusion criteria, with newly diagnosed OAG. Patients were randomised to either LTFC or DTFC for the first 1-month treatment phase after a 1-month washout period, without medical treatment, patients began with the opposite treatment for the second 1-month treatment period. Colour Doppler parameters in ophthalmic artery (OA) and posterior ciliary arteries (PCA), ocular perfusion pressure, IOP and systemic haemodynamics were assessed at each baseline and at the end of each treatment period. The main outcomes include peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistance index (RI) in OA and PCA. DTFC significantly increased EDV in OA from 7.55 (1.16) to 9.32 (1.22), p < 0.0001, and in the PCA from 4.41 (0.70) to 5.36 (0.60), p < 0.0001, and significantly decreased RI in OA from 0.775 (0.036) to 0.725 (0.032), p < 0.0001, and in the PCA from 0.694 (0.045) to 0.634 (0.034). LTFC significantly decreased the EDV and significantly increased RI in PCA, p = 0.0076 and p = 0.0009, respectively. There were no statistical significant differences in the IOP lowering effect between both treatments. DTFC seems to have a beneficial vascular effect on retrobulbar vessels in OAG patients.
Dr. A. Martinez, C/ Rosalia de Castro, N80 5C, 15895 Ames, La Coruna, Spain. tontxu_1999@yahoo.com
Classification:
6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
